Board of Directors
Managing Partner, The Column Group
Dr. Goeddel has served as chairman of our board of directors since January 2008 and served as our Chief Executive Officer from 2008 to 2010. Dr. Goeddel has been Managing Partner of The Column Group since 2007. He co-founded Tularik in 1991, was Vice President of Research until 1996 and Chief Executive Officer from 1996 through 2004, when Tularik was acquired by Amgen. He served as Amgen’s first Senior Scientific Vice President until May 2006. Prior to Tularik, he was the first scientist hired by Genentech, Inc. and from 1978 to 1993 served in various positions, including Fellow, Staff Scientist and Director of Molecular Biology. His pioneering work in the fields of gene cloning and expression of human proteins has been the basis for five significant marketed therapeutics developed by Genentech, including human insulin, human growth hormone, interferon-alpha, interferon-gamma and tissue plasminogen activator. Dr. Goeddel has received numerous scientific awards including the Scheele Medal, the Eli Lilly Award in Biological Chemistry, the Inventor of the Year Award, the Jacob Heskel Gabbay Award, the Howley Prize for Arthritis Research and the Warren Alpert Foundation Prize. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences.
Jin-Long Chen, Ph.D.
Founder And Chief Scientific Officer, NGM Biopharmaceuticals
Dr. Chen is the Company's Founder, and has served as a member of the board of directors and as the Chief Scientific Officer since January 2008. He was also NGM's President until November 2014. Previously, Dr. Chen held various positions at Amgen, most recently as its Vice President, Metabolic Disorders, with responsibility for leading the company's global research efforts in small molecule and biologic drug discovery for the treatment of human diseases affecting metabolism, bone, mineral balance and muscle. Prior to joining Amgen, he served as Vice President of Biology at Tularik where he guided drug discovery research in oncology, inflammation and metabolic disease. Dr. Chen's pioneering work on a broad array of targets at both Amgen and Tularik not only opened up opportunities to study new aspects of biology and physiology across disease areas, but also led to contributions of multiple drug candidates to the development pipelines of these organizations, including RepathaTM (evolocumab), a novel anti-PCSK9 antibody that lowers low-density lipoprotein cholesterol.
Dr. Chen received a B.S. in Nutrition and Food Science from Fu-Jen Catholic University, and a M.S. in biochemistry from National Taiwan University. He completed his graduate training at the University of California, Berkeley in 1994, receiving a Ph.D. for his research on the mechanisms of transcription carried out in the laboratory of Prof. Robert Tjian.
Managing Partner, Rho Capital Partners
Mr. Leschly is Managing Partner of Rho Capital Partners, an investment and venture capital management company. He has twenty years of experience in the venture capital and private equity business. Prior to joining Rho in 1999, he spent five years at Healthcare Ventures where he was a general partner. Previously, he had several years of management consulting experience at McKinsey & Company. In addition to a number of private company boards, his current and former board involvement in life sciences and healthcare includes: Anacor Pharmaceuticals, Gloucester Pharmaceuticals, Memory Pharmaceuticals, MPV, NitroMed, Senomyx, Tercica, Vanda Pharmaceuticals, Verenium (formerly Diversa) and Vicuron. Mr. Leschly received an A.B. from Harvard University and an M.B.A. from the Stanford Graduate School of Business.
William J. Rieflin
Chief Executive Officer, NGM Biopharmaceuticals
Mr. Rieflin joined NGM as Chief Executive Officer in 2010 and brings over 20 years of industry experience to the company. Most recently, he was President of XenoPort, Inc. (NASDAQ: XNPT). Prior to that, he was Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary for Tularik Inc. (NASDAQ: TLRK), which was acquired by Amgen Inc. in 2004. Previously, he was Vice President, Human Resources, General Counsel and Secretary for AMSCO International, Inc. (NYSE: ASZ). He was also an associate at Sidley & Austin in the corporate and securities department. He began his career as a sales representative for American Hospital Supply Corporation. He currently serves on the Board of Directors of Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), FLX Bio, Inc. and XenoPort. Mr. Rieflin earned his B.S. from Cornell University, his M.B.A. from the University of Chicago Booth School of Business and his J.D. from Stanford Law School.
Managing Director, Prospect Venture Partners
Dr. Schnell is a Managing Director and co-founder of Prospect Venture Partners, a series of dedicated life science venture capital funds with over a $1 billion under management since inception. Dr. Schnell has been actively involved in the formation and growth of numerous successful biomedical and health care companies. He currently serves on the Board of Directors of several private companies, and has served on the boards of Amira Pharmaceuticals (NYSE: BMS acquired), Gloucester Pharmaceuticals (NASDAQ:CELG acquired), Healtheon (NASDAQ: WBMD), Kythera Biopharmaceuticals (NASDAQ: KYTH), Microcide (NASDAQ:MCDE), Neurocrine (NASDAQ:NBIX), Rinat Neuroscience (NYSE:PFE acquired), Senomyx (NASDAQ:SNMX) and Trubion (NYSE: EBS acquired), among others. Dr. Schnell received an M.D. from Harvard Medical School, an M.A. in Health Services Research from Stanford University School of Medicine and a B.S. in Biological Sciences from Stanford University.
Managing Partner, The Column Group
Mr. Svennilson has twenty-nine years of experience in corporate finance, investment banking and venture capital. He is the Founder and Managing Partner of The Column Group, an early-stage venture capital group that has started or invested in approximately 16 biotech companies and manages funds totaling approximately $600 million. Mr. Svennilson was previously the founder and a partner of Three Crowns Capital, a backer of a new generation of U.S. biotechnology companies. Prior to Three Crowns Capital, he was the Associate Managing Director in charge of European Investment Banking Origination at Nomura Securities in London. He helped found companies like Rosetta, PTC, Tercica and Somalogic, and has helped finance and develop biotech companies such as Tularik, Sunesis, ChemoCentryx, Infinity, AVEO, Rinat and FivePrime. He is currently a member of the Board of Directors of NGM Biopharmaceuticals, Inc., ORIC Pharmaceuticals, Inc. and Immune Design Corp. and has previously served on boards of several other biotechnology companies including Aragon, Seragon, Rosetta, PTC, Somalogic and ChemoCentryx. Mr. Svennilson is currently a Trustee for The Institute for Advanced Study in Princeton, New Jersey. Mr. Svennilson earned an M.B.A. from the Stockholm School of Economics.
McHenry (Mac) T. Tichenor, Jr.
Managing Partner, Tichenor Ventures, LLC
Mr. Tichenor is a private investor, entrepreneur and philanthropist with broad experience in managing and growing successful businesses. Mr. Tichenor served as President, Chief Executive Officer and Director of Tichenor Media System, Inc., which he subsequently merged with the Hispanic Broadcasting Corporation and, ultimately, with Univision Communications. He has also served as a director of several public companies. Mr. Tichenor is currently Executive Director of WWWW Foundation (Quad W), a non-profit organization devoted, in part, to cancer research. He serves as Chairman of the Board of the Sarcoma Alliance for Research through Collaboration, a non-profit sponsor of clinical trials for the prevention, treatment and cure of sarcomas. He is active on various boards associated with The University of Texas, including the Chancellor’s Council Executive Committee, the Advisory Council of the McCombs School of Business, the MD Anderson Cancer Center Board of Visitors and the Southwestern Medical Foundation. Mr. Tichenor earned a B.A. with Honors in Plan II and an M.B.A. from The University of Texas at Austin, and an M.S. in biotechnology from The University of Texas at Dallas.